Sun Pharma Advanced Research surges; USFDA seeks more information
Reuters Market Eye - Sun Pharma Advanced Research Company surges 12.6 pct.
Heads towards biggest daily gain since April.
Gets complete response letter from U.S drug regulator for anti-Glaucoma drug application.
Glaucoma products sales in U.S. at $2 bln - company's investor update in Feb.
Company says additional information request from the U.S. Food and Drug Administration can be addressed on priority.
A complete response letter informs companies that an application cannot be approved by USFDA in its present form.
Also Read
(Reporting by Abhishek Vishnoi)